Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Tytuł:
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
Autorzy:
Matthew E. Tenold
Benjamin N. Moskoff
David J. Benjamin
Rasmus T. Hoeg
Aaron S. Rosenberg
Mehrdad Abedi
Joseph M. Tuscano
Brian A. Jonas
Temat:
acute myeloid leukemia
venetoclax (BCL-2 inhibitor)
hypomethylating agent
relapsed/refractory
real-world data
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
Frontiers in Oncology, Vol 11 (2021)
Wydawca:
Frontiers Media S.A., 2021.
Rok publikacji:
2021
Kolekcja:
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
2234-943X
Relacje:
https://www.frontiersin.org/articles/10.3389/fonc.2021.649209/full; https://doaj.org/toc/2234-943X
DOI:
10.3389/fonc.2021.649209
Dostęp URL:
https://doaj.org/article/952a0e9bb5b4475182416ad7275cd6bc  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.952a0e9bb5b4475182416ad7275cd6bc
Czasopismo naukowe
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8–24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies